GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Purchase Of Property, Plant, Equipment

ALVR (AlloVir) Purchase Of Property, Plant, Equipment : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is AlloVir Purchase Of Property, Plant, Equipment?

AlloVir's purchase of property, plant, equipment for the three months ended in Dec. 2024 was $0.00 Mil. It means AlloVir spent $0.00 Mil on purchasing property, plant, equipment. AlloVir's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00Mil.

Compared with last quarter ($0.00 Mil in Sep. 2024 ), AlloVir spent the same money on purchasing property, plant, equipment in Dec. 2024 ($0.00 Mil).

AlloVir Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for AlloVir's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Purchase Of Property, Plant, Equipment Chart

AlloVir Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial -0.24 -0.03 - - -

AlloVir Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AlloVir Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlloVir Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of AlloVir's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

AlloVir Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Purchase Of Property, Plant, Equipment
Comparable Companies
PRLD IMMX MAIA OTLK PDSB SER HRGN LTRN XLO TNXP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1661 Massachusetts Avenue, PO Box 44, Lexington, MA, USA, 02420
Website
https://www.allovir.com
AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).
Executives
Vikas Sinha director, 10 percent owner, officer: See Remarks C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Edward Miller officer: General Counsel C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen officer: Chief Accounting Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams director ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B officer: Chief Commercial Officer C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy officer: See Remarks C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal director, 10 percent owner, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2 director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018